Dickerson JW

Title : Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound - Bertron_2016_Bioorg.Med.Chem.Lett_26_4637

Author(s) : Bertron JL , Ennis EA , Tarr CJ , Wright J , Dickerson JW , Locuson CW , Blobaum AL , Rook JM , Blakely RD , Lindsley CW

Ref : Bioorganic & Medicinal Chemistry Lett , 26 :4637 , 2016

Abstract :

PubMedSearch : Bertron_2016_Bioorg.Med.Chem.Lett_26_4637

PubMedID: 27575469

Title : The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease - Jones_2012_J.Pharmacol.Exp.Ther_340_404

Author(s) : Jones CK , Bubser M , Thompson AD , Dickerson JW , Turle-Lorenzo N , Amalric M , Blobaum AL , Bridges TM , Morrison RD , Jadhav S , Engers DW , Italiano K , Bode J , Daniels JS , Lindsley CW , Hopkins CR , Conn PJ , Niswender CM

Ref : Journal of Pharmacology & Experimental Therapeutics , 340 :404 , 2012

Abstract :

PubMedSearch : Jones_2012_J.Pharmacol.Exp.Ther_340_404

PubMedID: 22088953

Dickerson JW

References (2)

1. Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound - Bertron_2016_Bioorg.Med.Chem.Lett_26_4637

2. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease - Jones_2012_J.Pharmacol.Exp.Ther_340_404